⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29870162 | 1.00 | — | — | |
| SCHEMBL18703941 | 0.81 | — | — | |
| SCHEMBL30876843 | 0.81 | — | — | |
| SCHEMBL8257576 | 0.77 | — | — | |
| SCHEMBL16972864 | 0.77 | — | — | |
| SCHEMBL30683717 | 0.75 | — | — | |
| SCHEMBL273776 | 0.75 | — | — | |
| SCHEMBL7065526 | 0.75 | — | — | |
| SCHEMBL13954212 | 0.73 | — | — | |
| SCHEMBL24538309 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 296 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747255-A1 | MODULATORS OF THE ADENOSINE A2A AND A2B RECEPTOR | Ryvu Therapeutics S.A. (PL) | 2026-05-27 | — | — | EP | disclosed |
| US-20260125398-A1 | 5,6-FUSED BICYCLIC ALCOHOL COMPOUNDS AS 15-PROSTAGLANDIN DEHYDROGENASE MODULATORS | AMGEN INC. (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4736856-A2 | BICYCLIC AMINES AS CDK2 INHIBITORS | Incyte Corporation (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260116881-A1 | KIF MODULATOR COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12583824-B2 | 6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficient CFTR activity | GENZYME CORPORATION (US) | 2026-03-24 | — | — | US | disclosed |
| EP-4709481-A1 | 5,6-FUSED AND 6,6-FUSED BICYCLIC ALCOHOLS AND ETHERS AND COMPOSITIONS FOR USE AS 15-PROSTAGLANDIN DEHYDROGENASE MODULATORS | Amgen Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4041731-B1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORP (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260022119-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION | 2026-01-22 | — | — | US | disclosed |
| EP-4126879-B1 | N-PHENYL SUBSTITUTED INDOLE DERIVATIVES AS MYT1 INHIBITORS FOR THE TREATMENT OF CANCER | REPARE THERAPEUTICS INC (CA) | 2026-01-21 | — | — | EP | disclosed |
| US-12466828-B2 | Bicyclic amines as CDK2 inhibitors | INCYTE CORPORATION (US) | 2025-11-11 | — | — | US | disclosed |
| EP-1107960-A1 | PYRAZINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2001-06-20 | — | — | EP | disclosed |
| US-6083951-A | FOR THE TREATMENT OF DISEASES OR MEDICAL CONDITIONS SUCH AS HYPERTENSION, PULMONARY HYPERTENSION, CARDIAC OR CEREBRAL CIRCULATORY DISEASE AND RENAL DISEASE | ZENECA LIMITED (GB) | 2000-07-04 | — | — | US | disclosed |
| CN-1253551-A | Pyrazine compounds | GLAXO GROUP LTD (GB) | 2000-05-17 | — | — | CN | disclosed |
| WO-2000012488-A1 | PYRAZINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |
| EP-0966448-A1 | PYRAZINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 1999-12-29 | — | — | EP | disclosed |
| EP-0752986-B1 | N-HETEROCYCLYL SULPHONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ZENECA LTD (GB) | 1999-05-19 | — | — | EP | disclosed |
| US-5861401-A | TREATMENT OF CONGESTIVE HEART FAILURE | ZENECA LIMITED (GB) | 1999-01-19 | — | — | US | disclosed |
| WO-1998038174-A1 | PYRAZINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 1998-09-03 | — | — | WO | disclosed |
| EP-0752986-A1 | N-HETEROCYCLYL SULPHONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ZENECA LIMITED (GB) | 1997-01-15 | — | — | EP | disclosed |
| WO-1995026957-A1 | N-HETEROCYCLYL SULPHONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ZENECA LIMITED (GB) | 1995-10-12 | — | — | WO | disclosed |